Skip to main content

Day: July 24, 2025

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.CGM+ combines sustainability with user-friendly design, featuring a compact wearable and reusable sensor applicator. Unlike traditional CGMs focused solely on glucose monitoring, CGM+ integrates an ultra-thin minimally...

Continue reading

Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth

Data presented at the UMDF meeting highlighting first three of expected six subjects and two compassionate use patients provide encouraging results supporting continuation of trial HAIFA, Israel, July 24, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces positive interim results of the ongoing Phase 2 trial of the Company’s lead investigational compound MNV-201 in Pearson Syndrome, a fatal pediatric mitochondrial disease characterized by sideroblastic anemia (a disorder causing abnormal red blood cell development), failure to thrive and exocrine pancreas dysfunction. The interim analysis was presented at the United Mitochondrial Disease Foundation (UMDF) Annual...

Continue reading

MACOM to Report Third Quarter 2025 Financial Results on August 7, 2025

LOWELL, Mass., July 24, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI) plans to announce financial results for its third quarter ended July 4, 2025, before market open on Thursday, August 7, 2025. In conjunction with the release, MACOM will conduct a conference call at 8:30 a.m. Eastern Time on Thursday, August 7, 2025, hosted by Mr. Stephen G. Daly, President and Chief Executive Officer, and Mr. John F. Kober, Senior Vice President and Chief Financial Officer. Please visit MACOM’s Investor Relations Website to register for a user-specific access code for the live call or to access the live webcast. A replay of the call will be available within 24 hours and remain accessible by all interested parties for approximately 90 days. About MACOMMACOM designs and manufactures high-performance...

Continue reading

SAIC Appoints David Urban to Board of Directors

Urban brings extensive experience at the intersection of policy, politics and strategy RESTON, Va., July 24, 2025 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC), the nation’s leading mission integrator, today announced that former senior advisor to President Trump and political strategist David Urban has been appointed to its Board of Directors, effective September 15, 2025. Urban has extensive experience across government, military, legal, private and public sectors, helping companies to navigate public policy and strategic communications challenges, as well as advising on corporate governance, risk management and organizational leadership. He will bring that wealth of expertise to his board position at SAIC. Mr. Urban has been appointed to serve on the Board’s Audit Committee and this increases SAIC’s...

Continue reading

Golar releases its 2024 Environmental, Social and Governance report

Golar LNG Limited is pleased to announce that it has issued its 2024 Environmental, Social and Governance (“ESG”) report. The report is attached and can also be found on our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended).  All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve...

Continue reading

Karat Packaging to Report 2025 Second Quarter Financial Results and Host Conference Call on Thursday, August 7, 2025

CHINO, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (“Karat” or the “Company”) (Nasdaq: KRT), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced it will release its 2025 second quarter financial results after market close on Thursday, August 7, 2025. The Company will host an investor conference call on the same day.Call Date: Thursday, August 7, 2025Time: 2:00 p.m. PT/5:00 p.m. ETPhone: 877-418-4045 (domestic); 412-317-6745 (international)Conference ID: Karat Packaging Inc.Webcast: Accessible at https://irkarat.com/events-presentations/; archive available for approximately one year   About Karat Packaging Inc. Karat Packaging Inc. is a specialty distributor and manufacturer of a wide range of disposable foodservice...

Continue reading

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409’s existing U.S. Food and Drug Administration (FDA) Orphan Drug Designation and FDA Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) awarded to CAN-2409 in April 2024 and December 2023, respectively, and underscores the significant unmet medical need in this disease beyond the U.S. CAN-2409 is an investigational, off-the-shelf, replication-defective...

Continue reading

StepStone Group to Announce First Quarter Fiscal 2026 Results on August 7, 2025

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the quarter ended June 30, 2025, after the market closes on Thursday, August 7, 2025. This represents results for the first quarter of the fiscal year ending March 31, 2026. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, August 7, 2025, at 5:00 pm ET to discuss the Company’s results for the first quarter of the fiscal year ending March 31, 2026. The webcast will be made available on the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. A replay will also be available on the shareholders...

Continue reading

Stellantis and 4screen Enhance In-Car Convenience with Real-Time, Location-Based Mobility Services

Stellantis and 4screen Enhance In-Car Conveniencewith Real-Time, Location-Based Mobility Services4screen platform brings real-time, location-based content into Stellantis vehicles across North America and EuropeCustomers can explore nearby locations such as restaurants, convenience stores, parking, gas and charging stations, and Stellantis brand dealerships – directly from the infotainment screen Results are personalized and contextual, with the option to filter and display only the most relevant points of interest (POIs) based on each journey First eligible vehicles have begun receiving the service, with a broader rollout across multiple brands and markets underway The experience will continue to expand as more businesses join 4screen’s growing partner networkAMSTERDAM and MUNICH – July 24, 2025 – Stellantis, one of the world’s...

Continue reading

Publishing of Suominen’s Half-Year Financial Report January–June 2025 on August 7, 2025

Suominen Corporation’s press release on July 24, 2025 at 3:00 p.m. (EEST) Suominen Corporation will publish its Half-Year Financial Report for January 1 – June 30, 2025 on Thursday, August 7, 2025 at approximately 9:30 a.m. (EEST). Janne Silonsaari, CFO and Interim President & CEO, will present the result in English in an audiocast and a conference call for analyst, investors, and media on the same day at 11:00 a.m. (EEST). The audiocast can be followed at https://suominen.events.inderes.com/q2-2025. The recording of the audiocast and the presentation material will be available after the event at www.suominen.fi. Conference call participants can access the teleconference by registering at https://palvelu.flik.fi/teleconference/?id=50051445. The phone numbers and a conference ID to access the conference will be provided after the registration. SUOMINEN...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.